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Introduction: higher blood pressure and organ damage were always observed in chronic hypertension.
Here, we have investigated in female uninephrectomized spontaneously hypertensive rats (UNX-SHRs) 
the role of NO on changes in blood pressure, renal function, thoracic aortic relaxations and structure.  
 
Materials and Methods: UNX-SHRs have been chronic treated with D-and L-arginine (D-and L-Arg; 1
mg kg-1 day-1 during 6 months in drinking water) alone or in the presence of low doses of Nw-nitro-L-
arginine methyl ester (L-NAME; 1 mg kg-1 day-1 the first month and 0.5 mg kg-1 day-1 during the next 5 
months in drinking water).  
Mean blood pressure (MAP) was measured by the tail-cuff procedure. Plasma and urine levels of
creatinine (Jaffé reaction), urinary proteins (Bradford method), as well as, urinary sodium and potassium
(flame photometer) were determined for to evaluate renal function.  
Nitrite production in plasma was also measured by the Griess reaction. Segments of thoracic aortas were
used to analyze vascular reactivity and morphology.  
 
Results: at the end of the study, the MAP was higher in UNX-SHRs treated with L-NAME+D-Arg and L-
NAME+L-Arg than D-or L-arginine alone. There were no differences between groups on renal function.  
Vascular relaxation induced by acetylcholine (endothelium-depedent relaxation) was higher in animals
treated by L-Arg vs. D-Arg, but was similar to L-NAME treated animals. In contract, vascular relaxation 
induced by sodium nitroprusside (endothelium-independent relaxation) was similar in all treated UNX-
SHRs.  
Structural changes in thoracic aorta were linked to pressure load, as well as, NO production.  
Conclusion: we could suggest in UNX-SHRs treated during 6 months with low doses of NO related drugs
that:  
a) renal dysfunction may be an independent process from vascular response and vascular reactivity;
and  
b) functional and structural changes in thoracic aorta seems to be linked to both pressure load, and
changes in NO production  
 
INTRODUCTION  
Página 1 de 10CIN'2003: López-Hernández y col. Free Papers / Comunicaciones libres / Comunic...
23/01/2009http://www.uninet.edu/cin2003/paper/lopezh.html
Abnormally elevated blood pressure is not the only characteristic of hypertension [1]. Alterations in the
function and structure of the cardiovascular organs are also among the hallmarks of this disease.
Endothelial dysfunction and hypertrophy of the arterial wall are two well-known, typical features in most
types of hypertension [2-4]. The cause-effect relationship between blood pressure and most of these other
characteristics is not completely understood. In addition, whereas there is a patent pressure dependent
component for most of the structural, and perhaps functional, alterations (or adaptations), there is evidence
of a pressure-independent, hormonal component as wall [4]. Accordingly, several studies have reported
the appearance of certain cardiovascular alterations already at the pre-hypertensive stage in genetic models
of hypertension [5-7].  
Spontaneously hypertensive rats (SHRs), a model of genetic hypertension [8, for review see reference 9],
has been used in combination with induced renal damage as an animal counterpart to hypertensive patients
that, for one cause or another, are subject to nephrectomy (UNX). In this model of glomerular
hypertension associated with proteinuria [10], the remnant renal mass undergoes a functional readjustment
that allows the maintenance of renal function and control of blood pressure [11]. Perhaps, hormonal
changes that appear in the aftermath of this renal adjustment may also reach the periphery and affect the
structure and function of, among others, the cardiovascular organs.  
Nitric oxide (NO), a heterodiatomic molecule, is produced in vascular endothelium [12, for review see
references 13-14] and renal tissue [15, for review see reference 16] by the L-arginine pathway. It is also 
known that NO participates actively in the functional and the structural homeostasis of the cardiovascular
and renal tissue [17-18, for review see references 19-21]. Moreover, several authors have proposed a role
of NO in the pathogenesis of hypertension NO [1, 22-23].  
Chronic NO synthesis inhibition has been used as a model of experimental hypertension [24, for review
see reference 25]. Although, the effect of NO synthesis inhibition has been assessed in UNX-SHRs to
study the mechanism leading to hypertension-induced chronic renal failure under NO synthesis inhibition 
[26-28], there are not studies that correlate both data with aortic vascular relaxations and structure. In
some way, it is analyzed genetic hypertension and the importance of NO on adaptive needs of the
organism, linking organ damage to blood pressure [29].  
Considering that differences in NO production can influence NO actions from a useful cellular signal to a
potential toxic oxidant [30], the present study was designed to examine changes in thoracic aortic
relaxation and structure (assessed by morphometry) in UNX-SHRs after a 6 months treatment with low 
doses of L-NAME (Nw-nitro-L-arginine methyl esther, an inhibitor NO) in the presence of D-arginine (D-
Arg) and L-arginine (L-Arg; the substrate of NO production) or D-and L-Arg alone. We have used D-Arg-
treated UNX-SHRs as control group, because this drug reduced blood pressure, but it is not a substrate for
NO formation [31].  
MATERIALS AND METHODS  
Animals and Surgery  
Experimental conditions were published previously [28]. Three month-old female SHR (190-200 g weight 
at the beginning of the study, Charles-Rives, Barcelona, Spain) were used for this study. Experiments were
carried out in female rats, because they have a greater modulation of pressure-induced myogenic tone by 
NO in large vessels than male SHR [32]. All animals were housed under constant conditions and
maintained on a standard rat chow (Panlab A.04) and free access to water. After a laparotomy, the left
kidney was removed under ether anesthesia.  
After a recovery period of three weeks, the UNX-SHR were randomly allocated into four experimental 
groups, and were subsequently treated during six months with:  
1. Group D-Arg (n = 12), which consisted of rats that received D-Arg (1 mg kg-1 day-1) in drinking 
water.  
2. Group L-Arg (n = 13), which consisted of rats that received L-Arg (1 mg kg-1 day-1) in drinking 
water.  
3. Group L-NAME+D-Arg (n = 14), which consisted of rats that received D-Arg (1mg kg-1 day-1) 
plus L-NAME (1 mg kg-1 day-1 during the first month and 0.5 mg kg-1 day-1 during the next 5
months) in drinking water.  
4. Group L-NAME+L-Arg (n = 14), which consisted of rats that received L-Arg (1mg kg-1 day-1) 
plus L-NAME (1 mg kg-1 day-1 during the first month and 0.5 mg kg-1 day-1 during the next 5
months) in drinking water.  
Water intake was continuously monitored to ensure the right dose ingestion. 
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Blood pressure was measured by the tail-cuff procedure [33]. To analyze renal function, UNX-SHRs were 
placed into individual metabolic cages 4 days, and afterwards urine free of food and faeces, was collected
daily into graduate cylinders under water-equilibrated mineral oil and 0.1% sodium azide during 2 days. A
blood sample (150 µl) was taken from the caudal vein of the animals for plasma creatinine measurements.
Then, the abdominal aortas were catheterized in UNX-SHRs under ether anaesthesia. Immediately, blood
samples (1 ml) were taken into heparinized ice-cold tubes, centrifuged at 4º C (700xg/10 min). Then, 
plasma samples were stored at -20º C to measure plasma nitrite levels by the Griess reaction [34].
Afterwards, an ice phosphate buffered saline solution was infused into abdominal aortas to wash out the
blood, then right kidneys and descending thoracic aortas were removed, cleaned of fat and conective
tissues and placed in gassed (95% O2, 5% CO2) Kreb´s solution of the following composition in mM:
NaCl 118.0, KCl 4.7, CaCl2 2.5, KH2PO4 1.2, MgSO4 1.2, NaHCO3 25.0 and glucose 11.1, pH of 7.4.
Aortas were cut transversally into 6-7 ring segments (3-4 mm in lenght), one of which was assigned to 
morphologic measurements and the rest to functional studies.  
Aortic reactivity  
The thoracic aortic rings were mounted between two stainless steel holders and set up in organ baths, filled
with Kreb´s solution and continuously gassed (95% O2, 5% CO2) The contractile force was measured
with an isometric force-displacement transducer (UF1, Grass Instruments) and registered on a MacLab
System (Macintosh Computers). Rings were allowed to equilibrate during 60 min a resting tension of 2 g.
Their functional capacity was tested by exposing them to 105 mM KCl. Then, rings were submitted to a
repeated washing, to return tension to basal levels, and a new relapse period of 30 min. Cumulative
concentration-response curves to 3 x 10-8 - 10-4 M acetylcholine (ACh; endothelium-dependent 
relaxation) and 10-9 - 3 x 10-6 M sodium nitroprusside (SNP; endothelium-independent relaxation) were
obtained, respectively in aorta rings precontracted with a submaximal dose of NA (10-6 M). The thoracic 
aortic rings were allowed to a 30 min recovery period in resting tension before the use of each relaxing
agent. Data are expressed as percentage of dilatation with respect to NA-induced preconstraction.  
The IC50 (expressed as negative logarithm of the molar concentration, pD2) of thoracic aortas is the
concentrations of the test agents that induce a 50% of relaxation.  
Aortic morphology  
Segments of thoracic aortas, assigned to morphologic studies, were fixed by immersion in 4% p-
formaldehyde and embedded in paraffin. 5 µm thick sections of thoracic aortas were cut with a microtome
(E. Leitz Wetzlar, Germany) and placed on slides. The paraffin was removed by heating at 56ºC overnight. 
The tissues were stained with hematoxylin-eosin. The aortic images were captured with a light Nikon
microscopy and photographed using a Nikon FX-35A camera and analyzed with a digitizing board 
(Kontron model IBAS I). Aortic wall thickness (w, mm) was calculated as the difference between the
external aortic radius (Re, mm) and the internal aortic radius (Ri, mm). The media-to-lumen ratio values 
were calculated as w/Ri. Circumferential wall stress (kPa; 1 mmHg = 133.3 kPa) was calculated as MAP.
2w/Di, where Di (mm) is the internal diameter [35].  
Analytic Methods  
Plasma and urine levels of creatinine were determined by a colorimetric method based in Jaffé reaction
[36]. Urinary proteins were analyzed by the Bradford method [37]. Urinary sodium and potassium were
performed using a flame photometer. For to measure nitrite levels by the Griess reaction [34], plasma
samples (500 µl) were incubated with Griess reagent (250 µl) during 15 min at room temperature before 
reading the absorbance. NO2- concentration was determined with reference to a standard curve by using
concentrations from 1-75 µM NaNO2. Griess reaction (1879): Nitrite reacts with 1% sulfanilamide in 5%
H3PO4/0.1% naphthalene-ethylenediamine dihydrochloride forming a chromophore (pink to dark red
color) absorbing at 540 nm.  
Statistical analysis  
All values are expressed as means ± SEM of the indicated number of individual observations.
Comparisons among groups were analyzed by analysis of variance and the Scheffé´s test, for the in vivo
study. *P<0.05 was considered statistically significant. For vascular reactivity and structure, comparisons
between groups were analyzed by analysis of variance and the Student´s t test. *P<0.05 was considered
statistically significant.  
Drugs  
L-NAME hydrochloride, D-and L-Arg, ACh hydrochloride, NA bitartrate and NSP were all purchased
from Sigma-Aldrich (Madrid, Spain). Drug solutions were made in distilled water, except for NA which
was prepared in an acid solution (0.01% ascorbic acid w/v). In the case of vascular relaxations, all drug
concentrations are expressed as the final molar concentration in the organ chamber for vascular reactivity.
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Figure 1. Changes in blood pressure (A) and plasma nitrite levels (B) at the end of the study. UNX-SHRs were treated during 
six months with: D-Arg (1 mg kg-1 min-1; strong hatch columns), L-Arg (1 mg kg-1 min-1; open columns) alone or in the 
presence of L-NAME (1 mg kg-1 min-1 the first month and 0.5 mg kg-1 min-1 the next five months; respectively light hatch 
and close columns). Each symbol represents the mean + SEM of at least 12 animals. *P<0.05 vs. D-Arg, # P<0.05 vs. L-Arg.  
Renal parameters were summarized in Table II. The creatinine clearance, urinary flow, proteinuria and 
sodium excretion were similar in all the treated UNX-SHRs.  
 
RESULTS  
In vivo study  
At 6 months of treatment, the survival of the different animal groups was: 100% for D-Arg, 92% for L-
Arg, 78% for L-NAME+D-Arg and 64% for L-NAME+L-Arg. There were not significant differences 
between groups on body weight, water intake, heart rate or organ weights (Table I). Mean blood pressure
(MAP) rose significantly in the two groups that received L-NAME when compared with those receiving 
D-or L-Arg alone (Figure 1a). Plasma nitrite levels were significantly higher in the L-Arg vs. other three 
groups (Figure 1b).  
Table I. Body weights, organ weights and haemodynamics parameters in the four groups of treated 
uninephrectomized spontanoeusly hypertensive rats (UNX-SHRs). 





D-Arg 12 235±4 16.0±1.5 1.73±0.07 5.23±0.20 412±10
L-Arg 13 238±3 16.2±1.1 1.67±0.11 5.31±0.17 409±17
L-NAME+D-
Arg 14 238±3 16.4±1.3 1.94±0.11 5.45±0.12 418±7
L-NAME+L-Arg 14 236±4 17.7±1.9 1.98±0.12 5.45±0.22 410±26
D-Arg indicates D-arginine (1 mg kg-1 day-1), L-Arg indicates L-arginine (1 mg kg-1 day-1), L-NAME 
indicates Nw-nitro-L-arginine methyl ester (1 mg kg-1 min-1 the first month and 0.5 mg kg-1min-1 the next five 
months), BW indicates body weight, WI indicates water intake; AW indicates aorta weight, KW indicates kidney 
weight, HR indicates heart rate. Values are means ± SEM *P<0.05 vs. D-Arg; #P<0.05 vs. L-Arg. 
Table II. Parameters of renal function in the four groups of treated UNX-SHRs.
Urinary flow (µl Ccr (ml min- PROT (mg 24 UNaV (mEq 24 UKV (mEq 24 
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Acetylcholine-and nitroprusside-induced vasorelaxations  
Addition of NA (10-6 M) to rat thoracic aortic rings induced in different treated UNX-SHRs a contraction 
of: D-Arg = 2826 + 160 mg (n =18), L-Arg = 2396 + 210 mg (n =15), L-NAME+D-Arg = 2337+149 mg 
(n =18) and L-NAME+L-Arg = 2435+112 mg (n =18). Data on vascular relaxations were summarized in 
Figure 2 and and Table III. The response was significantly higher (p<0.01) in the D-Arg group in 
comparison with others. In NA (10-6M)-precontracted rings, the sensitivity and Emax in concentration-
responses curves to ACh were significantly reduced in vessels of D-Arg treated-animals vs. other treated-
groups. However, in NA (10-6 M)-precontracted rings, although there were differences in the sensitivity 
between groups in concentration-responses curves to SNP (a nitric oxide-donor) the Emax effects were 
similar. 
  
Figure 2. Concentration-response curves for acetylcholine (Ach; A and B) and sodium nitroprusside (SNP; C) in throracic aorta 
rings of UNX-SHRs. Results are expressed as percentage dilatation after noradrenaline (10-6 M)-induced precontraction. Rats 
were treated during six months with: D-Arg (1 mg kg-1 min-1), L-Arg (1 mg kg-1 min-1) alone or in the presence of L-NAME 
(1 mg kg-1 min-1 the first month and 0.5 mg kg-1min-1 the next five months). Each symbol represents the mean + SEM of at 
least 6 aortic rings. *P<0.05 vs. D-Arg.  
Treatment n min-1) 1) h-1) h-1) h-1)
D-Arg 12 4.19±0.28 0.827±0.074 3.93±0.60 0.335±0.042 0.256±0.031
L-Arg 13 4.26±0.45 0.963±0.071 4.01±0.59 0.318±0.054 0.253±0.040
L-NAME+D-
Arg 14 4.76±0.39 1.009±0.076 5.64±0.86 0.251±0.036 0.240±0.036
L-NAME+L-
Arg 14 5.10±0.40 0.917±0.060 6.41±1.14 0.204±0.053 0.167±0.036
Ccr indicates creatinine clearance, PROT indicates proteinuria, UnaV indicates urinary sodium excretion, UKV indicates 
urinary potassium excretion. Values are means ± SEM. 
Table III. Maximal relaxation, and sensibility of thoracic aortic rings of treated UNX-SHRs.
Treatment D-Arg L-Arg L-NAME+D-Arg L-NAME+L-Arg
pD2 Emax(%) pD2 Emax(%) pD2 Emax(%) pD2 Emax(%)
Relaxation
ACh 4.22±0.10 52.5±9.0 7.53±0.09 97.4±4.4 5.61±0.20* 73.8±6.5* 7.00±0.05* 106.0±10.6
† 
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Aortic structure  
Table IV and Figure 3 show the effects of different treatments in thoracic aortic structure. The mean 
internal diameter was similar in all treated UNX-SHRs. However, the wall thickness, media-to-lumen ratio 
and media-cross-sectional area where significantly higher in the L-NAME+D-Arg group in comparison 
with others. It is interesting to observe some differences between L-NAME+L-Arg treated-animals vs. 




Figure 3. Aortic thickness/mean arterial pressure ratio (A) and circumferential wall stress (B) of UNX-SHRs. Rats were treated 
during six months with D-Arg (1 mg kg-1 min-1; A: open circles and B: strong hatch columns); L-Arg (1 mg kg-1 min-1; A: 
open squarts and B: open columns); L-NAME+D-Arg (1 mg kg-1 min-1 the first month and 0.5 mg kg-1 min-1 the next five 
months plus D-Arg; A: close circles and B: light hatch columns); and L-NAME+L-ARG (1 mg kg-1 min-1 during the first 
month and 0.5 mg kg-1 min-1 during the next five months plus L-Arg; A: close squarts and B: close columns). Each symbol 
represents the mean + SEM of at least four data. *P<0.05 vs. D-Arg, #P<0.05 vs. L-Arg and † P<0.05 vs. L-NAME+D-Arg.  
 
DISCUSSION  
In view of the kidney and blood pressure are closely related [38] and a renal defect may represent the 
response of the kidney to the hypertensive progress [39]; we have investigated in this study the long-term 
role of NO on aortic vessels in a mixed experimental process: a nephron reduction that accelerate renal 
lesions [40] and SHR, an animal model of essential hypertension [8-9]. According plasma nitrite levels 
measured at the end of the study, a chronic administration of low doses of L-NAME, were able to blunt 
NO-production induced by 1 mg kg-1 day-1 of L-Arg. However, L-NAME aggravates blood pressure in 
this model after 6 months of administration, with or without L-Arg, and indicates that NO is not the main 
NPS 5.56±0.05* 80.6±6.7* 7.99±0.02* 104.0±4.0 5.02±0.14* 100.0±5.3 7.68±0.01 100.0±5.3
ACh indicates acetylcholine, NPS indicates sodium nitroprusside. The values are means ± SEM of at 
least 6 experiments. *P<0.05 vs. D-Arg, #P<0.05 vs. L-Arg and †P<0.05 vs. L-NAME+L-Arg. 
Table IV. Morphometric variables measured in thoracic aortas of UNX-SHRs.
Treatment D-Arg L-Arg L-NAME+D-Arg L-NAME+L-Arg
mean internal diameter (mm) 1.42 + 0.06 1.37 + 0.03 1.44 + 0.03 1.45 + 0.04
wall thickness (mm) 0.129 + 0.001 0.123 + 0.010 0.167 + 0.005* 0.144 + 0.009
media-to-lumen ratio 0.18 + 0.01 0.18 + 0.01 0.23 + 0.01* 0.20 + 0.01
media cross-sectional area (mm2) 0.63 + 0.01 0.56 + 0.06 0.86 + 0.04* 0.72 + 0.05
Values are means + SEM of at least 4 data. *p<0.05 vs. D-Arg and #p<0.05 vs. L-Arg. 
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regulator of blood pressure, after the renal resetting that occurs upon UNX in genetic hypertension. NO 
synthesis blockade also induced hypertrophy of the aortic wall of UNX-SHRs, but this structural change is 
more related on blood pressure rise than NO production. This finding is probably one of the most 
important ones in this work. The other interesting finding of this study is that those UNX-SHRs treated 
with L-NAME+L-Arg have low survival, perhaps adaptation to maintain high blood pressure makes 
necessary to preserve the abnormal vascular structure.  
Endothelial dysfunction is a typical characteristic of hypertension. It is the result of an imbalance in the 
normal equilibrium between endothelial contracting and relaxing factors [2, 41-43]. Both pressure-
dependent and -independent factors have been implicated in its appearance [2]. Particularly in SHRs, NO 
production upon stimulation is normal or even elevated, but it is partially neutralized by an abnormally 
excessive production of oxygen reactive species [44-45]. Here, we show that neither long-term NO 
synthesis inhibition nor supplementation with L-Arg induces significant changes in the intrinsic relaxation 
capacity of the aorta (whether endothelium-dependent or -independent). This means that, in our model, the 
behavior of the aortic wall as regards its capacity of relaxation is not determined by the blood pressure 
levels and its consequences, but rather by genetic or pre-established determinants. All groups have a 
similar aortic relaxation profile in spite of being subject to starkly different pressure levels.  
When we tested vascular reactivity, we found some differences between groups on NA-induced 
contraction. If vascular tone and sympathetic response could be dependent on NO release [46], our data on 
NA-precontracted vessels are clear the consequence of these effects. In the aftermath of the present results 
on vasorelaxations, we can conclude that this status is not altered by the presence or absence of NO in the 
aortic wall. The resultant endothelial imbalance seems not to be dependent on further pressure increase or 
on NO status, since all groups showed a similar response to ACh, except D-Arg. The modification of other 
endothelium-derived factors, as a consequence of an adaptation pressure load, with a reciprocal regulation 
of their production with NO would be implicated on this response. In fact, two important local endothelial 
vasoconstrictors such as arginine II and endothelin-1 would be regulated according NO synthesis [27, 42, 
47]. In additional, it is demonstrated that a vasoconstrictor factor derived from cyclooxygenase pathway is 
up regulated in the vascular wall of UNX-SHRs [48]. Some of these products of arachidonic acid such as 
20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids (EETs) or prostaglandin H2 and 
tromboxane A2 may be also regulated by NO production [49-52]. It is also interesting to observe that the 
endothelial hyperpolarizing relaxing factor, actually considered as a derivate of EETs, is dependent on 
cytochrome P450 [53]. If we block NO production with L-NAME that is also able to inhibit EETs 
formation, because its blocks the reduction of ferric cytochrome C by ferrous ion [54], perhaps we are 
increasing blood pressure by two different sites.  
When morphometric results were analyzed in UNX-SHRs, it is interesting to observe on aortic wall a 
different degree of MAP with the same internal diameter, as previous reported [55-57], which could be 
related again to an endothelial dysfunction. Nervertheless, we can not discard a possible role of NO in 
vascular cell growth [58-59], according data of the L-NAME+D-ARG group on wall thickness and media 
cross-sectional area; we demonstrate some differences in arterial walls of large arteries as an adaptative 
process leading to regulate blood flow [35], when data on aortic structural changes were corrected with the 
MAP. Rat aortic structure has been studied extensively in hypertension in SHRs [60, for review see 
reference 61] and NO deficiency using high doses of L-NAME [62], but not one has linked essential 
hypertension with renal mass reduction, chronic NO inhibition and structural changes in large arteries for a 
long time. Although, our structural changes in aortas of UNX-SHRs were not so large, because doses of 
different NO drugs were very low; its evidences that NO could modify the adaptative process to 
hypertension of large arteries by means of a low dose of L-ARG; in fact, L-NAME+L-ARG treated 
animals had a significant reduction in circumferential wall stress and wall thickness/MAP in comparison 
with L-NAME + D-ARG group and this could explain the different survival of the animals.  
Finally, according our data there are not significant differences in renal function among groups. All groups 
of UNX-SHRs, regardless of the treatment they have received, reset the remaining kidney to achieve 
normal renal performance. However, those animals with their NO-pathway blocked by L-NAME 
administration, needed higher blood pressure to maintain both a normal renal function and a balance in 
sodium excretion, in agreement with the well-known role of NO on the relationship between blood 
pressure/intraglomerular pressure and natriuresis/diuresis [63-65]. It is interesting to observe that L-
NAME did not inhibit L-Arg effects. Perhaps, L-Arg transport into cells might be altered or reset after 
UNX, as previous reported in humans with renal damage [66], and the main control of renal function 
would not depend on NO actions.  
In conclusion we could suggest in UNX-SHRs treated during 6 months with low doses of NO related 
drugs that: a) renal dysfunction may be an independent process from vascular response and vascular 
reactivity; and b) functional and structural changes in thoracic aorta seems to be linked to both pressure 
load, and changes in NO production.  
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